<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03609008</url>
  </required_header>
  <id_info>
    <org_study_id>Levcromakalim &amp; MRI</org_study_id>
    <nct_id>NCT03609008</nct_id>
  </id_info>
  <brief_title>The Effect of Levcromakalim Infusion on the Cranial Arteries Over Several Hours Using a High Resolution MRA Technique in a Randomized, Double-blind Placebo-controlled Design in Healthy Volunteers.</brief_title>
  <official_title>The Effect of Levcromakalim Infusion on the Cranial Arteries Over Several Hours Using a High Resolution MRA Technique in a Randomized, Double-blind Placebo-controlled Design in Healthy Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danish Headache Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Danish Headache Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Healthy participants vill randomly be allocated in a 2:1 order to receive 1 mg levcromakalim
      or placebo (isotonic saline) for 20 min.

      The investigator here examine the effect of levcromakalim infusion on the MMA and the MCA
      circumference over several hours using a high resolution MRA technique in a randomized,
      double-blind placebo-controlled design in healthy volunteers. The investigator hypothesized
      that levcromakalim induces dilatation of cranial arteries.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Healthy participants vill randomly be allocated in a 2:1 order to receive 1 mg levcromakalim
      or placebo (isotonic saline) for 20 min.

      The investigator here examine the effect of levcromakalim infusion on the MMA and the MCA
      circumference over several hours using a high resolution MRA technique in a randomized,
      double-blind placebo-controlled design in healthy volunteers. The investigator hypothesized
      that levcromakalim induces dilatation of cranial arteries.

      MR imaging will be performed on a 3.0 Tesla Philips Achieva Scanner (Philips Medical Systems,
      Best, The Netherlands) using an eight-element phased-array receiver head coil. We will obtain
      repeated MRA measurements covering the MMA and MCA before and after levcromakalim/placebo
      infusion
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 26, 2018</start_date>
  <completion_date type="Actual">August 15, 2018</completion_date>
  <primary_completion_date type="Actual">August 15, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, double-blind placebo-controlled study with healthy volunteers.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change is assessed of cranaial arteries; MMA, STA and MCA</measure>
    <time_frame>Before and after infusion of levcromakalim compared with before and after infusion of saline. Time of measurements is baseline, 20 min, 110 min, 200 min, 290 min and 350 min after the infusion.</time_frame>
    <description>The investigator will obtain repeated MRA measurements covering the diameter of MMA and MCA before and after levcromakalim/placebo infusion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Headache</measure>
    <time_frame>Before (-10 min) and after infusion (+16 hours) of levcromakalim compared with before and after infusion of saline</time_frame>
    <description>Headache intensity will be recorded on a verbal rating scale (VRS) from 0 to 10 (0, no headache; 1, a feeling of pressure; 10, worst imaginable headache).
Time of headache measurements is before (-10 min) and after infusion (+16 hours) of levcromakalim compared with before and after infusion of saline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Dilatation of Cranial Arteries; MMA, STA and MCA</condition>
  <condition>Headache</condition>
  <arm_group>
    <arm_group_label>Levcromakalim</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>18 participants will randomly be allocated in a 2:1 order to receive 1 mg levcromakalim or placebo (isotonic saline)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>18 participants will randomly be allocated in a 2:1 order to receive 1 mg levcromakalim or placebo (isotonic saline)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levcromakalim</intervention_name>
    <description>Intravenous administration of levcromakalim or placebo for 20 minutes. To investigate the role of levcromakalim/placebo on cerebral hemodynamic in healthy volunteers.</description>
    <arm_group_label>Levcromakalim</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Intravenous administration of levcromakalim or placebo for 20 minutes. To investigate the role of levcromakalim/placebo on cerebral hemodynamic in healthy volunteers.</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers of both sexes.

          -  18-60 years.

          -  50-100 kg.

          -  Women of childbearing potential must use adequate contraception.

        Exclusion Criteria:

          -  A history of serious somatic disease

          -  Migraine or any other type of headache (except episodic tension-type headache less
             than once a month)

          -  Daily intake of any medication except contraceptives

          -  Contraindications for MRI scan.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Danish headache center</name>
      <address>
        <city>Copenhagen</city>
        <state>Glostrup</state>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>June 26, 2018</study_first_submitted>
  <study_first_submitted_qc>July 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2018</study_first_posted>
  <last_update_submitted>March 19, 2019</last_update_submitted>
  <last_update_submitted_qc>March 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Danish Headache Center</investigator_affiliation>
    <investigator_full_name>Mohammad Al-Mahdi Al-Karagholi</investigator_full_name>
    <investigator_title>MD, PhD student</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cromakalim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

